HK1009331A1 - Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders - Google Patents

Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders

Info

Publication number
HK1009331A1
HK1009331A1 HK98110056A HK98110056A HK1009331A1 HK 1009331 A1 HK1009331 A1 HK 1009331A1 HK 98110056 A HK98110056 A HK 98110056A HK 98110056 A HK98110056 A HK 98110056A HK 1009331 A1 HK1009331 A1 HK 1009331A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
treatment
neurodegenerative disorders
enantiomeric
ethylamine
Prior art date
Application number
HK98110056A
Other languages
English (en)
Inventor
Ronald Conrad Griffith
Robert John Murray
Michael Balestra
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of HK1009331A1 publication Critical patent/HK1009331A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK98110056A 1992-04-03 1998-08-21 Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders HK1009331A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
HK1009331A1 true HK1009331A1 (en) 1999-05-28

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110056A HK1009331A1 (en) 1992-04-03 1998-08-21 Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders

Country Status (29)

Country Link
EP (1) EP0633879B1 (xx)
JP (2) JP3120810B2 (xx)
KR (1) KR100259567B1 (xx)
CN (1) CN1044367C (xx)
AT (1) ATE163925T1 (xx)
AU (2) AU3897693A (xx)
CA (1) CA2133427C (xx)
CZ (1) CZ288519B6 (xx)
DE (1) DE69317411T2 (xx)
DK (1) DK0633879T3 (xx)
DZ (1) DZ1677A1 (xx)
ES (1) ES2115055T3 (xx)
FI (1) FI105025B (xx)
HK (1) HK1009331A1 (xx)
HU (1) HU211529A9 (xx)
IL (1) IL105276A (xx)
MA (1) MA22866A1 (xx)
MX (1) MX9301935A (xx)
MY (1) MY110149A (xx)
NO (1) NO302170B1 (xx)
NZ (1) NZ251384A (xx)
PL (1) PL180014B1 (xx)
RU (1) RU2128650C1 (xx)
SG (1) SG47948A1 (xx)
SK (1) SK281258B6 (xx)
TW (1) TW282455B (xx)
UA (1) UA29437C2 (xx)
WO (1) WO1993020052A1 (xx)
ZA (1) ZA932415B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
CA2748235A1 (en) * 2008-12-24 2010-07-01 Astrazeneca Ab Ethanamine compounds and their use for treating depression
EP2791352A1 (en) 2011-12-14 2014-10-22 Astrazeneca AB Gabr-a2 diagnostic
TR201909632T4 (tr) * 2013-11-05 2019-07-22 Astrazeneca Ab Nmda antagonisti ön ilaçları.
US20230190719A1 (en) * 2020-06-23 2023-06-22 Biohaven Therapeutics Ltd. Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
FI105025B (fi) 2000-05-31
JPH07505385A (ja) 1995-06-15
IL105276A (en) 1997-06-10
DE69317411D1 (de) 1998-04-16
ZA932415B (en) 1993-10-22
EP0633879B1 (en) 1998-03-11
KR100259567B1 (ko) 2000-07-01
NO943645L (no) 1994-11-16
HU211529A9 (en) 1995-11-28
FI944546A (fi) 1994-09-30
DK0633879T3 (da) 1998-09-28
AU3897693A (en) 1993-11-08
CN1044367C (zh) 1999-07-28
MX9301935A (es) 1994-08-31
CA2133427A1 (en) 1993-10-14
NO943645D0 (no) 1994-09-30
AU7545696A (en) 1997-02-13
TW282455B (xx) 1996-08-01
WO1993020052A1 (en) 1993-10-14
RU94042465A (ru) 1996-07-20
CN1081669A (zh) 1994-02-09
DE69317411T2 (de) 1998-07-30
FI944546A0 (fi) 1994-09-30
MA22866A1 (fr) 1993-12-31
UA29437C2 (uk) 2000-11-15
AU705419B2 (en) 1999-05-20
NO302170B1 (no) 1998-02-02
SK281258B6 (sk) 2001-01-18
JP2000319259A (ja) 2000-11-21
EP0633879A1 (en) 1995-01-18
CZ288519B6 (cs) 2001-07-11
ES2115055T3 (es) 1998-06-16
ATE163925T1 (de) 1998-03-15
CA2133427C (en) 2003-06-10
IL105276A0 (en) 1993-08-18
PL180014B1 (pl) 2000-11-30
SG47948A1 (en) 1998-04-17
MY110149A (en) 1998-02-28
SK117794A3 (en) 1995-05-10
CZ240994A3 (en) 1995-12-13
DZ1677A1 (fr) 2002-02-17
NZ251384A (en) 1996-10-28
JP3120810B2 (ja) 2000-12-25
RU2128650C1 (ru) 1999-04-10

Similar Documents

Publication Publication Date Title
PL331822A1 (en) Application of a chelating agent clioquinole in production of a pharmaceutic agent designed for use in treatment of alzheimer disease
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
AU6611396A (en) New oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
HK1009331A1 (en) Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders
AU7227394A (en) Method for surface treatment, means for carrying out the method and the use thereof
EP0676477A3 (de) Vorrichtung und Verfahren zum Einschlagen oder Buggen.
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
CA2135710A1 (en) Melatonin derivatives for use in treating desynchronization disorders
HRP931016A2 (en) Thienothiazin derivatives, process for the preparation and application thereof
AU1496597A (en) 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's Disease
AU8715491A (en) Melatonin derivative having therapeutic activity in dermatology
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
AU1402592A (en) Process for the selective reduction of the 4-halogen in 2,4-dihaloanilines
AU647608B2 (en) Isoxazolylimidazole derivatives, process for their production and their use in pharmaceutical agents
EP0636611A3 (en) Optically active 1,4-dihydropyridine derivatives and process for preparing the same.
HUT76806A (en) Technetium-sulphonamide complexes, their use, pharmaceutical agents containing them, and process for producing the complexes and agents
AU3218195A (en) Alpha-d-pentofuranoside derivatives, process for preparing the same and their use
AU1557797A (en) 2,3-disubstituted cyclopentanone derivatives, process for producing the same, and medicinal use thereof
EP0714659A3 (en) Indole derivatives in the treatment of emesis
AU7183298A (en) Melatonin derivatives for use in treating desynchronization disorders
AU8701298A (en) 2,3-dihydro-benzofuranol derivatives and process for resolving the same
AU663520C (en) Medicaments for treating gastrointestinal disorders
HU9603287D0 (en) Pharmaceutical composition, use thereof and process for producing the active component
IL108785A0 (en) Process for the preparation of (1r,2r),n-methyl-2(3-pyridyl)-tetrahydrothiopyran-2-carbothioamide 1-oxide

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20130331